<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04377945</url>
  </required_header>
  <id_info>
    <org_study_id>BK-JM-201</org_study_id>
    <nct_id>NCT04377945</nct_id>
  </id_info>
  <brief_title>Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components</brief_title>
  <acronym>SHINE</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study in Parkinson's Disease Patients With Dyskinesia to Assess the Efficacy and Safety/Tolerability of Fixed Dose Combinations of JM-010 and Its Individual Components</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bukwang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bukwang Pharmaceutical</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two-part, double-blind, placebo-controlled, randomized, multicenter Phase 2
      clinical trial of JM-010 in patients with Parkinsons' Disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two-part, Phase 2, double-blind, placebo-controlled, randomized, multicentre study.

      Subjects with a diagnosis of PD and moderate to severe dyskinesias in PD will complete a
      Screening Visit to assess eligibility to participate in the study. Subjects will continue
      with their usual levodopa treatment regimen for the duration of study participation.

      The screening assessment period will be from 1 week to 6 weeks duration. For both Part 1 and
      Part 2, subjects deemed eligible at the end of the Screening Visit will be randomly assigned
      in a 1:1:1:1 ratio to receive one of the treatments, as per the double-blind study design.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 4, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 12, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Unified Dyskinesia Rating Scale (UDysRS)</measure>
    <time_frame>12 Weeks (Part 2)</time_frame>
    <description>Unified Dyskinesia Rating Scale (Scoring range: 0-104), higher score indicates more severe dyskinesia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Unified Dyskinesia Rating Scale (UDysRS)</measure>
    <time_frame>Week 1, 2, and 3 (Part 1), Week 2, 4, 8, and 12 (Part 2)</time_frame>
    <description>Unified Dyskinesia Rating Scale (Scoring range: 0-104), higher score indicates more severe dyskinesia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS)</measure>
    <time_frame>Week 1, 2, and 3 (Part 1), Week 2, 4, 8, and 12 (Part 2)</time_frame>
    <description>Movement Disorder Society Unified Parkinson's Disease Rating Scale (Scoring range: 0-132), higher score indicates more severe motor impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician's Global Impression-Change (CGI-C) score</measure>
    <time_frame>Week 3 (Part 1), Week 12 (Part 2)</time_frame>
    <description>Clinician's Global Impression-Change (Scoring range: 0-7), 0=not assessed; 1=very much improved; 2=much improved; 3=a little improved; 4=no change; 5=minimally worse; 6=much worse; and 7=very much worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hauser diary</measure>
    <time_frame>Week 2, 4, 8, and 12 (Part 2)</time_frame>
    <description>Hauser Diary (Recording total time with dyskinesia changes)</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">188</enrollment>
  <condition>Dyskinesia, Drug-Induced</condition>
  <arm_group>
    <arm_group_label>Part 1, JM-010 component Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1, JM-010 component Group A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, JM-010 component Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1, JM-010 component Group B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, JM-010 component Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1, JM-010 component Group C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part 1, Placebo Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, JM-010 combination Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2, JM-010 combination Group A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, JM-010 combination Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2, JM-010 combination Group B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part 2, Placebo Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, JM-010 component Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2, JM-010 component Group C</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 1, JM-010 component Group A</intervention_name>
    <description>JM-010 component Group A</description>
    <arm_group_label>Part 1, JM-010 component Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 1, JM-010 component Group B</intervention_name>
    <description>JM-010 component Group B</description>
    <arm_group_label>Part 1, JM-010 component Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 1, JM-010 component Group C</intervention_name>
    <description>JM-010 component Group C</description>
    <arm_group_label>Part 1, JM-010 component Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 1, Placebo Group</intervention_name>
    <description>Placebo Group</description>
    <arm_group_label>Part 1, Placebo Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 2, JM-010 combination Group A</intervention_name>
    <description>JM-010 combination Group A</description>
    <arm_group_label>Part 2, JM-010 combination Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 2, JM-010 combination Group B</intervention_name>
    <description>JM-010 combination Group B</description>
    <arm_group_label>Part 2, JM-010 combination Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 2, Placebo Group</intervention_name>
    <description>Placebo Group</description>
    <arm_group_label>Part 2, Placebo Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 2, JM-010 component Group C</intervention_name>
    <description>JM-010 component Group C</description>
    <arm_group_label>Part 2, JM-010 component Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is able to read, understand, and provide written, dated informed consent prior to
             Screening Visit.

          -  Is male or female, between 18 and 80 years of age at Screening Visit.

          -  Is diagnosed with idiopathic PD that meets UK Parkinson's Disease Society (UKPDS)
             Brain Bank Clinical Diagnostic Criteria and requires treatment with and shows
             responsiveness to levodopa.

          -  Has experienced dyskinesia over a period of at least 3 months prior to Screening Visit

          -  Has stable peak-effect dyskinesia

          -  Has more than one hour of &quot;ON&quot; time with troublesome dyskinesia during daily waking
             hours on a 24-hour PD subject diary

          -  Is on a stable levodopa dosing regimen requiring at least 3 dose administrations but
             no more than 6 dose administrations per day

        Exclusion Criteria:

          -  Has undergone surgery for the treatment of PD

          -  Has a current diagnosis of Substance Use (including alcohol) Disorder (Abuse or
             Dependence, as defined by Diagnostic and Statistical Manual, Fifth Edition [DSM 5]),

          -  Has psychiatric diagnosis of acute psychotic disorder or other psychiatric diagnoses

          -  Has a significant risk for suicidal behavior in the opinion of the investigator during
             the course of their participation in the study

          -  Has current seizure disorders (other than febrile seizures in childhood) requiring
             treatment with anticonvulsants.

          -  Has known serious ongoing symptomatic cerebral disease or cerebrovascular disease or
             any acute brain trauma requiring treatment with anti-convulsant therapy within 5 years
             prior Visit 2, Week 0 (Baseline Visit).

          -  Has a history of exclusively diphasic, OFF state, myoclonic, dystonic, or akathetic
             dyskinesia without peak-dose dyskinesia.

        Other criteria related to other medical conditions to be referred to the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoonjung Choi</last_name>
    <role>Study Director</role>
    <affiliation>Bukwang Pharmaceutical</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yoonjung Choi</last_name>
    <phone>82-2-828-8114</phone>
    <email>yoon.jung.choi@bukwang.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hyejin Roh</last_name>
    <phone>82-2-828-8114</phone>
    <email>hye.jin.roh@bukwang.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bukwang Investigator site</name>
      <address>
        <city>West Bloomfield</city>
        <state>Michigan</state>
        <zip>48322</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Bukwang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 4, 2020</study_first_submitted>
  <study_first_submitted_qc>May 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2020</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
    <mesh_term>Dyskinesia, Drug-Induced</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

